SI-BONE (NASDAQ:SIBN) & InfuSystem (NYSE:INFU) Critical Comparison

SI-BONE (NASDAQ:SIBN) and InfuSystem (NYSE:INFU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Valuation & Earnings

This table compares SI-BONE and InfuSystem”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$167.18 million	3.89	-$43.34 million	($0.76)	-20.13
InfuSystem	$134.86 million	0.89	$870,000.00	$0.10	57.20

InfuSystem has lower revenue, but higher earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

98.1% of SI-BONE shares are held by institutional investors. Comparatively, 71.1% of InfuSystem shares are held by institutional investors. 3.9% of SI-BONE shares are held by company insiders. Comparatively, 10.2% of InfuSystem shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for SI-BONE and InfuSystem, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0	0	6	0	3.00
InfuSystem	0	0	0	2	4.00

SI-BONE currently has a consensus price target of $24.50, suggesting a potential upside of 60.13%. InfuSystem has a consensus price target of $13.00, suggesting a potential upside of 127.27%. Given InfuSystem’s stronger consensus rating and higher probable upside, analysts clearly believe InfuSystem is more favorable than SI-BONE.

Risk & Volatility

SI-BONE has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, InfuSystem has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Profitability

This table compares SI-BONE and InfuSystem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SI-BONE	-23.82%	-22.51%	-16.53%
InfuSystem	1.12%	2.78%	1.41%

Summary

InfuSystem beats SI-BONE on 11 of the 15 factors compared between the two stocks.

About SI-BONE

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.